Glenmark Pharmaceuticals Limited is the first company in India to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination (FDC). With this new launch, Glenmark aims to improve glycemic control in adult patients with uncontrolled type-2 diabetes, especially the ones with comorbidities
This anti-diabetic FDC medication will be marketed under brand name Zita D. Glenmark’s Zita D is priced at around Rs 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and Rs 15 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 10mg, per day.
“Glenmark being a leader in the diabetes segment in India is proud to bring Zita D, a well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities”, said Alok Malik, EVP & Business Head, India Formulations, Glenmark Pharmaceuticals.
